1
|
Cioce A, Bineva-Todd G, Agbay AJ, Choi J, Wood TM, Debets MF, Browne WM, Douglas HL, Roustan C, Tastan OY, Kjaer S, Bush JT, Bertozzi CR, Schumann B. Optimization of Metabolic Oligosaccharide Engineering with Ac 4GalNAlk and Ac 4GlcNAlk by an Engineered Pyrophosphorylase. ACS Chem Biol 2021. [PMID: 33835779 DOI: 10.1021/acschem-bio.1c00034] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 04/19/2023]
Abstract
Metabolic oligosaccharide engineering (MOE) has fundamentally contributed to our understanding of protein glycosylation. Efficient MOE reagents are activated into nucleotide-sugars by cellular biosynthetic machineries, introduced into glycoproteins and traceable by bioorthogonal chemistry. Despite their widespread use, the metabolic fate of many MOE reagents is only beginning to be mapped. While metabolic interconnectivity can affect probe specificity, poor uptake by biosynthetic salvage pathways may impact probe sensitivity and trigger side reactions. Here, we use metabolic engineering to turn the weak alkyne-tagged MOE reagents Ac4GalNAlk and Ac4GlcNAlk into efficient chemical tools to probe protein glycosylation. We find that bypassing a metabolic bottleneck with an engineered version of the pyrophosphorylase AGX1 boosts nucleotide-sugar biosynthesis and increases bioorthogonal cell surface labeling by up to two orders of magnitude. A comparison with known azide-tagged MOE reagents reveals major differences in glycoprotein labeling, substantially expanding the toolbox of chemical glycobiology.
Collapse
Affiliation(s)
- Anna Cioce
- Department of Chemistry, Imperial College London, 80 Wood Lane, W12 0BZ London, United Kingdom
- The Chemical Glycobiology Laboratory, The Francis Crick Institute, 1 Midland Road, NW1 1AT London, United Kingdom
| | - Ganka Bineva-Todd
- The Chemical Glycobiology Laboratory, The Francis Crick Institute, 1 Midland Road, NW1 1AT London, United Kingdom
| | - Anthony J Agbay
- Department of Chemistry, Stanford University, Stanford, California 94305, United States
| | - Junwon Choi
- Department of Chemistry, Stanford University, Stanford, California 94305, United States
| | - Thomas M Wood
- Department of Chemistry, Stanford University, Stanford, California 94305, United States
| | - Marjoke F Debets
- Department of Chemistry, Stanford University, Stanford, California 94305, United States
| | - William M Browne
- Department of Chemistry, Imperial College London, 80 Wood Lane, W12 0BZ London, United Kingdom
- The Chemical Glycobiology Laboratory, The Francis Crick Institute, 1 Midland Road, NW1 1AT London, United Kingdom
| | - Holly L Douglas
- Mycobacterial Metabolism and Antibiotic Research Laboratory, The Francis Crick Institute, 1 Midland Road, NW1 1AT London, United Kingdom
| | - Chloe Roustan
- Structural Biology Science Technology Platform, The Francis Crick Institute, NW1 1AT London, United Kingdom
| | - Omur Y Tastan
- The Chemical Glycobiology Laboratory, The Francis Crick Institute, 1 Midland Road, NW1 1AT London, United Kingdom
| | - Svend Kjaer
- Structural Biology Science Technology Platform, The Francis Crick Institute, NW1 1AT London, United Kingdom
| | - Jacob T Bush
- GlaxoSmithKline, Gunnels Wood Road, Stevenage, Hertfordshire SG1 2NY United Kingdom
| | - Carolyn R Bertozzi
- Department of Chemistry, Stanford University, Stanford, California 94305, United States
- Howard Hughes Medical Institute, 380 Roth Way, Stanford, California 94305, United States
| | - Benjamin Schumann
- Department of Chemistry, Imperial College London, 80 Wood Lane, W12 0BZ London, United Kingdom
- The Chemical Glycobiology Laboratory, The Francis Crick Institute, 1 Midland Road, NW1 1AT London, United Kingdom
| |
Collapse
|
2
|
Cioce A, Bineva-Todd G, Agbay AJ, Choi J, Wood TM, Debets MF, Browne WM, Douglas HL, Roustan C, Tastan OY, Kjaer S, Bush JT, Bertozzi CR, Schumann B. Optimization of Metabolic Oligosaccharide Engineering with Ac 4GalNAlk and Ac 4GlcNAlk by an Engineered Pyrophosphorylase. ACS Chem Biol 2021; 16:1961-1967. [PMID: 33835779 PMCID: PMC8501146 DOI: 10.1021/acschembio.1c00034] [Citation(s) in RCA: 20] [Impact Index Per Article: 6.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/18/2022]
Abstract
![]()
Metabolic oligosaccharide
engineering (MOE) has fundamentally contributed
to our understanding of protein glycosylation. Efficient MOE reagents
are activated into nucleotide-sugars by cellular biosynthetic machineries,
introduced into glycoproteins and traceable by bioorthogonal chemistry.
Despite their widespread use, the metabolic fate of many MOE reagents
is only beginning to be mapped. While metabolic interconnectivity
can affect probe specificity, poor uptake by biosynthetic salvage
pathways may impact probe sensitivity and trigger side reactions.
Here, we use metabolic engineering to turn the weak alkyne-tagged
MOE reagents Ac4GalNAlk and Ac4GlcNAlk into
efficient chemical tools to probe protein glycosylation. We find that
bypassing a metabolic bottleneck with an engineered version of the
pyrophosphorylase AGX1 boosts nucleotide-sugar biosynthesis and increases
bioorthogonal cell surface labeling by up to two orders of magnitude.
A comparison with known azide-tagged MOE reagents reveals major differences
in glycoprotein labeling, substantially expanding the toolbox of chemical
glycobiology.
Collapse
Affiliation(s)
- Anna Cioce
- Department of Chemistry, Imperial College London, 80 Wood Lane, W12 0BZ London, United Kingdom
- The Chemical Glycobiology Laboratory, The Francis Crick Institute, 1 Midland Road, NW1 1AT London, United Kingdom
| | - Ganka Bineva-Todd
- The Chemical Glycobiology Laboratory, The Francis Crick Institute, 1 Midland Road, NW1 1AT London, United Kingdom
| | - Anthony J. Agbay
- Department of Chemistry, Stanford University, Stanford, California 94305, United States
| | - Junwon Choi
- Department of Chemistry, Stanford University, Stanford, California 94305, United States
| | - Thomas M. Wood
- Department of Chemistry, Stanford University, Stanford, California 94305, United States
| | - Marjoke F. Debets
- Department of Chemistry, Stanford University, Stanford, California 94305, United States
| | - William M. Browne
- Department of Chemistry, Imperial College London, 80 Wood Lane, W12 0BZ London, United Kingdom
- The Chemical Glycobiology Laboratory, The Francis Crick Institute, 1 Midland Road, NW1 1AT London, United Kingdom
| | - Holly L. Douglas
- Mycobacterial Metabolism and Antibiotic Research Laboratory, The Francis Crick Institute, 1 Midland Road, NW1 1AT London, United Kingdom
| | - Chloe Roustan
- Structural Biology Science Technology Platform, The Francis Crick Institute, NW1 1AT London, United Kingdom
| | - Omur Y. Tastan
- The Chemical Glycobiology Laboratory, The Francis Crick Institute, 1 Midland Road, NW1 1AT London, United Kingdom
| | - Svend Kjaer
- Structural Biology Science Technology Platform, The Francis Crick Institute, NW1 1AT London, United Kingdom
| | - Jacob T. Bush
- GlaxoSmithKline, Gunnels Wood Road, Stevenage, Hertfordshire SG1 2NY United Kingdom
| | - Carolyn R. Bertozzi
- Department of Chemistry, Stanford University, Stanford, California 94305, United States
- Howard Hughes Medical Institute, 380 Roth Way, Stanford, California 94305, United States
| | - Benjamin Schumann
- Department of Chemistry, Imperial College London, 80 Wood Lane, W12 0BZ London, United Kingdom
- The Chemical Glycobiology Laboratory, The Francis Crick Institute, 1 Midland Road, NW1 1AT London, United Kingdom
| |
Collapse
|
3
|
Debets MF, Tastan OY, Wisnovsky SP, Malaker SA, Angelis N, Moeckl LKR, Choi J, Flynn H, Wagner LJS, Bineva-Todd G, Antonopoulos A, Cioce A, Browne WM, Li Z, Briggs DC, Douglas HL, Hess GT, Agbay AJ, Roustan C, Kjaer S, Haslam SM, Snijders AP, Bassik MC, Moerner WE, Li VSW, Bertozzi CR, Schumann B. Metabolic precision labeling enables selective probing of O-linked N-acetylgalactosamine glycosylation. Proc Natl Acad Sci U S A 2020; 117:25293-25301. [PMID: 32989128 DOI: 10.1101/2020.04.23.057208] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 05/23/2023] Open
Abstract
Protein glycosylation events that happen early in the secretory pathway are often dysregulated during tumorigenesis. These events can be probed, in principle, by monosaccharides with bioorthogonal tags that would ideally be specific for distinct glycan subtypes. However, metabolic interconversion into other monosaccharides drastically reduces such specificity in the living cell. Here, we use a structure-based design process to develop the monosaccharide probe N-(S)-azidopropionylgalactosamine (GalNAzMe) that is specific for cancer-relevant Ser/Thr(O)-linked N-acetylgalactosamine (GalNAc) glycosylation. By virtue of a branched N-acylamide side chain, GalNAzMe is not interconverted by epimerization to the corresponding N-acetylglucosamine analog by the epimerase N-acetylgalactosamine-4-epimerase (GALE) like conventional GalNAc-based probes. GalNAzMe enters O-GalNAc glycosylation but does not enter other major cell surface glycan types including Asn(N)-linked glycans. We transfect cells with the engineered pyrophosphorylase mut-AGX1 to biosynthesize the nucleotide-sugar donor uridine diphosphate (UDP)-GalNAzMe from a sugar-1-phosphate precursor. Tagged with a bioorthogonal azide group, GalNAzMe serves as an O-glycan-specific reporter in superresolution microscopy, chemical glycoproteomics, a genome-wide CRISPR-knockout (CRISPR-KO) screen, and imaging of intestinal organoids. Additional ectopic expression of an engineered glycosyltransferase, "bump-and-hole" (BH)-GalNAc-T2, boosts labeling in a programmable fashion by increasing incorporation of GalNAzMe into the cell surface glycoproteome. Alleviating the need for GALE-KO cells in metabolic labeling experiments, GalNAzMe is a precision tool that allows a detailed view into the biology of a major type of cancer-relevant protein glycosylation.
Collapse
Affiliation(s)
- Marjoke F Debets
- Department of Chemistry, Stanford University, Stanford, CA 94305
| | - Omur Y Tastan
- The Chemical Glycobiology Laboratory, The Francis Crick Institute, NW1 1AT London, United Kingdom
| | | | - Stacy A Malaker
- Department of Chemistry, Stanford University, Stanford, CA 94305
| | - Nikolaos Angelis
- Stem Cell and Cancer Biology Laboratory, The Francis Crick Institute, NW1 1AT London, United Kingdom
| | | | - Junwon Choi
- Department of Chemistry, Stanford University, Stanford, CA 94305
| | - Helen Flynn
- Proteomics Science Technology Platform, The Francis Crick Institute, NW1 1AT London, United Kingdom
| | - Lauren J S Wagner
- Department of Chemistry, University of California, Berkeley, CA 94720
| | - Ganka Bineva-Todd
- The Chemical Glycobiology Laboratory, The Francis Crick Institute, NW1 1AT London, United Kingdom
- Peptide Chemistry Science Technology Platform, The Francis Crick Institute, NW1 1AT London, United Kingdom
| | | | - Anna Cioce
- The Chemical Glycobiology Laboratory, The Francis Crick Institute, NW1 1AT London, United Kingdom
- Department of Chemistry, Imperial College London, W12 0BZ London, United Kingdom
| | - William M Browne
- The Chemical Glycobiology Laboratory, The Francis Crick Institute, NW1 1AT London, United Kingdom
- Department of Chemistry, Imperial College London, W12 0BZ London, United Kingdom
| | - Zhen Li
- The Chemical Glycobiology Laboratory, The Francis Crick Institute, NW1 1AT London, United Kingdom
- Department of Chemistry, Imperial College London, W12 0BZ London, United Kingdom
| | - David C Briggs
- Signalling and Structural Biology Laboratory, The Francis Crick Institute, NW1 1AT London, United Kingdom
| | - Holly L Douglas
- Mycobacterial Metabolism and Antibiotic Research Laboratory, The Francis Crick Institute, NW1 1AT London, United Kingdom
| | - Gaelen T Hess
- Department of Genetics, Stanford University, Stanford, CA 94305
- Program in Cancer Biology, Stanford University, Stanford, CA 94305
| | - Anthony J Agbay
- Department of Chemistry, Stanford University, Stanford, CA 94305
| | - Chloe Roustan
- Structural Biology Science Technology Platform, The Francis Crick Institute, NW1 1AT London, United Kingdom
| | - Svend Kjaer
- Structural Biology Science Technology Platform, The Francis Crick Institute, NW1 1AT London, United Kingdom
| | - Stuart M Haslam
- Department of Chemistry, Imperial College London, W12 0BZ London, United Kingdom
| | - Ambrosius P Snijders
- Proteomics Science Technology Platform, The Francis Crick Institute, NW1 1AT London, United Kingdom
| | - Michael C Bassik
- Department of Genetics, Stanford University, Stanford, CA 94305
- Program in Cancer Biology, Stanford University, Stanford, CA 94305
| | - W E Moerner
- Department of Chemistry, Stanford University, Stanford, CA 94305
| | - Vivian S W Li
- Stem Cell and Cancer Biology Laboratory, The Francis Crick Institute, NW1 1AT London, United Kingdom
| | - Carolyn R Bertozzi
- Department of Chemistry, Stanford University, Stanford, CA 94305
- Howard Hughes Medical Institute, Stanford, CA 94305
| | - Benjamin Schumann
- The Chemical Glycobiology Laboratory, The Francis Crick Institute, NW1 1AT London, United Kingdom;
- Signalling and Structural Biology Laboratory, The Francis Crick Institute, NW1 1AT London, United Kingdom
| |
Collapse
|